PBM/LLLT shows the clearest short-term analgesic signal for BMS versus inactive control, but transportability remains uncertain given null-crossing prediction intervals and limited long-term data. Future trials should standardize outcomes, extend follow-up, and report harms transparently to support diagnosis-stratified care.
Calabrò et al. (2026) studied this question.